

Free Radical Research

Official Journal of the Society for Free Radical Research–European Region and the Society
for Free Radical Research–Asia



Editors-in-Chief

Michael Davies and Helmut Sies

**Abstracts of the Society for
SFRR – Europe Meeting 2009,
Rome, August 26–29, 2009**

informa
healthcare

Free Radical Research

Official Journal of the Society of Free Radical Research – European Region

Board of Editors

Editors-in-Chief:

Michael Davies

Heart Research Institute, Faculty of Medicine,
University of Sydney
114 Pyrmont Bridge Road
Camperdown, Sydney, NSW 2050
Australia
Tel: +61 2 8208 8900, Fax: +61 2 9565 5584
Email: daviesm@hri.org.au

Helmut Sies

Institute for Biochemistry and Molecular Biology I
Heinrich-Heine-University Dusseldorf
University Street 1, Building 22.03
D-40225-Dusseldorf, Germany
Tel: +49-211-811-5956, Fax: +49-211-811-5980
Email: sies@uni-duesseldorf.de

Associate Editors

Tilman Grune

University of Hohenheim
Nutrition Biofunctionality and Food Safety
Garbenstrasse 28
D-70593 Stuttgart, Germany
Tel: +49 (0)711 459-24060
Email: grune@uni-hohenheim.de

Jeffrey N. Keller

Pennington Biomedical Research Center, LSU System
6400 Perkins Road
Baton Rouge, LA 70808-4124, USA
Tel: 225-763-3190, Fax: 225-763-3193
Email: jeffrey.keller@pbrc.edu

Frank J Kelly

Pharmaceutical Science Research Division
King's College
London SE1 9NN, United Kingdom
Tel: 020 7848 4004, Fax: 020 7848 3891
Email: frank.kelly@kcl.ac.uk

Shinya Toyokuni

Department of Pathology and Biological Responses
Graduate School of Medicine, Nagoya University
65 Tsurumai-cho, Showa-ku
Nagoya 466-8550, Japan
Tel: +81-52-744-2086, Fax: +81-52-744-2091
Email: toyokuni@med.nagoya-u.ac.jp

Reviews Editors

Regina Brigelius-Flohe

Dept. Biochemistry of Micronutrients
German Institute of Human Nutrition
Potsdam-Rehbruecke
Arthur-Scheunert-Allee 114-116
D-14558 Nuthetal, Germany
Tel: +49 33200 88 353, Fax: +49 33200 88 407
Email: flohe@dife.de

Christian Schöneich

Department of Pharmaceutical Chemistry
University of Kansas
236C Simons Lawrence
KS 66045, USA
Phone: (785) 864-4880
Fax: (785) 864-5736
Email: schoneic@ku.edu

Editorial Board

Takaaki Akaïke, Kumamoto

Angelo Azzi, Boston

Enrique Cadenas, Los Angeles

Kevin Croft, Perth

Chris Cooper, Colchester

Helen Griffiths, Birmingham

Malcolm Jackson, Liverpool

Dean Jones, Atlanta

Lars-Oliver Klotz, Dusseldorf

Santiago Lamas, Madrid

Joao Laranjinha, Coimbra

Giovanni Mann, London

Mike Murphy, Cambridge

William Orr, Dallas

Henrik Poulsen, Copenhagen

Holly van Remmen, San Antonio

Jeremy Spencer, Reading

Young-Joon Surh, Seoul

José Vina, Valencia

Aims and Scope

Free Radical Research aims to publish high-quality research papers, hypotheses and reviews in all areas in the fields of:

- Free radicals and other reactive species in biological, clinical, environmental and other systems
- Redox signalling
- Antioxidants, including diet-derived antioxidants and other relevant aspects of human nutrition
- Oxidative damage, mechanisms and measurement

Manuscripts should contribute a significant advance to the field, supported by clearly-presented data and statistical analysis, where necessary. Manuscripts should be as concise as possible subject to the need to present relevant background, data and methods. Reviewers are strongly encouraged to identify areas of the manuscript that could be shortened. *Free Radical Research* discourages papers that are purely descriptive (e.g. a catalogue of changes in antioxidant levels in a human disease or after administering, for example, a plant extract or a toxin to an animal). We also discourage screening papers, such as the use of total antioxidant activity assays to compare the antioxidant activities of plant extracts or herbal medicines including traditional medicines.

Further information about the Journal, including links to the online sample copy and contents pages, can be found on the Journal homepage: www.informaworld.com/FreeRadicalResearch

Informa Healthcare makes every effort to ensure the accuracy of all the information (the "Content") contained in its publications. However, Informa Healthcare and its agents and licensors make no representations or warranties whatsoever as to the accuracy, completeness or suitability for any purpose of the Content and disclaim all such representations and warranties whether express or implied to the maximum extent permitted by law. Any views expressed in this publication are the views of the authors and are not the views of Informa Healthcare.

Abbreviations

ML	Main Lecture
PL	Plenary Lecture
WL	Workshop Lecture
YIA	Young Investigator Award Lecture
OP	Oral Presentation
VESS	Vitamin E Statellite Meeting
P	Poster

Contents**Introductory Remarks**

S2

Titles of Presentations

S3

Abstracts

Main Lecture	S27
Plenary Lecture (PL I-V)	S29
Workshop Lecture (WL I-VI)	S33
YIA Lecture	S38
Oral Presentaion (OP I-VI)	S41
VESS	S53
Poster (P I-VI)	S59

Alphabetical list of authors

S98

We may thanks to

S107

trophil's functionality, assessed by phagocytosis and metabolic activity (VEGA 2/0090/08, APVV-51-017905, APVV-21-055205, COST B35).

PVI-12 YIA

Novel 1,2,4-triazole-3-acetate derivatives combining anti-inflammatory and antioxidant properties

A. Poptsis, E.A. Rekka, P.N. Kourounakis

Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotelian University of Thessaloniki, Thessaloniki 54124, Greece

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used agents for the treatment of inflammation and highly prescribed medications. However, the common NSAIDs possess major side-effects, mainly gastrointestinal complications. It is also well known that reactive oxygen species are implicated in inflammation. Therefore, anti-inflammatory agents devoid of the gastrointestinal side-effects and combining antioxidant activity may be an important therapeutic tool for long anti-inflammatory treatment.

Substituted 1,2,4-triazole-3-acetates have been reported to acquire anti-inflammatory activity with reduced gastrointestinal toxicity. Having these properties in mind, we designed and developed some substituted analogues of 1,2,4-triazole-3-acetate amidated with an antioxidant molecule, such as trimethoxybenzoic acid or 3,5-di-tert-butyl-4-hydroxybenzoic acid. It is therefore anticipated that these compounds would acquire combined anti-inflammatory activity without the above-mentioned drawbacks, as well as antioxidant protection. The synthesis of the novel compounds, along with the results on the reduction on the caragennan-induced paw oedema in rats, their effect on inflammation enzymes and the ability of the molecules to inhibit lipid peroxidation of rat hepatic microsomal membranes will be presented. Finally, an attempt to correlate structural characteristics and their contribution to the overall activity will be made.

PVI-13

Reactive oxygen metabolites and chronic low intensity inflammation in haemodialysed patients-influence of age and duration of haemodialysis

T. Ruskovska, R. Antarov

Central Clinical Laboratory, Military Hospital, Skopje, Macedonia and Department of Internal Medicine, Military Hospital, Skopje, Macedonia

Chronic low intensity inflammation and increased oxidative stress are recognized as important risk factors for morbidity and mortality in haemodialysed patients.

The aim of this study was to elucidate the connection between reactive oxygen metabolites (dROMs), hsCRP, age and duration of haemodialysis.

In the beginning of study both hsCRP (original immuno-turbidimetric method for Olympus AU400) and dROMs (Diacron, application for Olympus AU400) were measured. During the follow-up only hsCRP was measured (three, six and ten months later). Only patients with lowest value (or at least within the same class: < 1; 1-3; > 3 mg/l) of hsCRP at first measurement were included.

Patients fulfilling inclusion criteria were divided in three groups: I group (n=24) with dROMs lower than 400 (normal and low to middle level of oxidative stress; only three of them had normal levels of oxidative status: 250-300); II group (n=13) with dROMs 401-500 (high level of oxidative stress); III group (n=8) with dROMs over 501 CARR U (very high level of oxidative stress).

There was a statistically significant difference for hsCRP between first and third group (1.59 ± 1.16 : 11.91 ± 10.21 mg/l; $p < 0.05$) and second and third group (1.72 ± 1.27 : 11.91 ± 10.21 mg/l; $p < 0.05$). There was also a statistically significant difference for age between first and third group (57 ± 10 : 67 ± 11 years; $p < 0.05$) and first and second group (57 ± 10 : 66 ± 11 years; $p < 0.025$). There was not a significant difference for duration of haemodialysis between these three groups.

PVI-14

Isoprostanes as biomarkers of borreliosis development

E. Skrzydlewska, W. Luczaj, A. Moniuszko, M. Rusak, S. Pancewicz, J. Zajkowska

Medical University of Białystok

Among agents transmitted by ticks, a significant role in human pathology play viruses of tick borne-encephalitis and spirochaetes *Borrelia burgdorferi* sensu lato. Because course of tick-borne encephalitis (TBE) and borreliosis are accompanied by inflammation and oxidative stress formation, levels of MDA and 8-iso-PGF₂ α , as potential biomarkers of development of these diseases, were measured. MDA (HPLC) and 8-iso-PGF₂ α (LCMS) were determined in plasma, cerebrospinal fluid and urine of patients with clinical symptoms of neuroborreliosis (7 patients) and tick-borne encephalitis (12 patients). MDA level was found to be higher by 20% in plasma, by 25% in cerebrospinal fluid and by 15% in urine in patients with suspected neuroborreliosis compared to control group. However MDA level was higher by 25% in plasma, by 28% in cerebrospinal fluid and by 10% in urine in patients with diagnosed TBE compared to the control group. The level of isoprostanes was increased 10 times in plasma, 7 times in the cerebrospinal fluid and 5 times in the urine of patients with suspected neuroborreliosis compared to the controls. However in case of patients diagnosed with tick-borne encephalitis, the level of isoprostanes was increased 4 times in the plasma, 3 times in the cerebrospinal fluid and 2 times in the urine compared to the control. Simultaneously, changes in the levels of isoprostanes in the plasma, cerebrospinal fluid and urine were found to be in correlation with one another. Therefore, it might be suggested that determination of isoprostanes in the urine or plasma should confirm clinical diagnosis in which case the examination of cerebrospinal fluid will not be necessary.

PVI-15

Improvement of total antioxidant capacity a possible bioeffect of the ultrasound therapy

R. Ungur, M. Dronca, I. Onac, T. Kaucsar, I.M. Borda, L. Pop

"Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj Napoca, Romania

The importance of the oxidative stress in osteoarthritis (OA) is well renowned at present. The ultrasound therapy is successfully used nowadays to treat OA, but without precise understanding of the mechanism of action.

The present study has monitored the effects of the ultrasound therapy over the clinical and functional parameters and over the antioxidant status in patients with OA.

A group of 12 patients diagnosed with OA were treated with ultrasound therapy: 0,5 W/cm², 5 minutes, 10 sessions (5 times/week). Before and in the end of the therapy were measured the Womac score (WS), the Laquesne index (LI), and the total antioxidant status (TAS) by using colorimetric method and Rel Assay kit.

A statistically significant amelioration ($p < 0.05$) was observed regarding all studied parameters (WS, LI and TAS).

The increase of the total antioxidant capacity could represent one of the mechanisms through which the ultrasound therapy exerts its favorable effects in OA.

PVI-16

Inhibition of nitric oxide production prevents apoptotic features mediated by inflammation in immature neurons

A.R. Vaz, S. Leitão Silva, A. Barateiro, A. Fernandes, A.S. Falcão, R.F.M. Silva, M.A. Brito, D. Brites

Centro Patogénese Molecular - iMed.UL, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal